MBI News
- 04/26/2012
Epizyme Forms Strategic Partnership with Industry Leader in Epigenetic Therapies, Celgene Corporation, to Develop Personalized Therapeutics for Genetically-Defined Cancers - 04/09/2012
Nuron Biotech Expands Portfolio With Exclusive, Worldwide License for an Amyloid Beta 42 DNA Vaccine Candidate for Alzheimer’s Disease - 03/20/2012
Aerpio Announces Positive Phase 1 Data on First-in-class Tie2 Activator, AKB-9778, in Development for Diabetic Macular Edema - 03/07/2012
Mersana Therapeutics Enters Collaboration with Endo Pharmaceuticals to Develop Next-generation Antibody-drug Conjugates - 03/05/2012
Nuron Biotech Expands Portfolio With License of Therapeutic and Prophylactic Hepatitis Vaccine Candidates - 02/23/2012
Satori Pharmaceuticals Raises $15M in New Funding - 02/21/2012
Enanta Enters Into Strategic Collaboration To Advance NS5A Inhibitor Candidate For HCV - 02/13/2012
OncoPep Enters Exclusive License Agreement with Dana-Farber for Novel Multi-peptide Vaccine Technology for Hematologic Cancers - 02/09/2012
Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation - 02/09/2012
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium - 02/07/2012
Thrasos and Collaborators Publish Nature Medicine Research Article Detailing Potential Treatment Approach for Kidney Disease - 02/02/2012
Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD) - 01/13/2012
Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market - 01/10/2012
FORMA Therapeutics Announces an Exclusive Cancer Drug Discovery Alliance Focused on Tumor Metabolism with Janssen Biotech Inc. - 01/10/2012
Epizyme Achieves $4 Million Pre-Clinical Milestone Payment in Eisai Strategic Partnership - 01/05/2012
FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs - 01/04/2012
CircuLite Awarded Grant from Cardiovascular Medical Research and Education Fund to Develop Right-Heart Circulatory Support System for Patients with Pulmonary Arterial Hypertension (PAH) - 12/15/2011
Rheonix, Inc. Announces Novel Microarray Production Technology to Support Multiplexed Endpoint Detection of Single Nucleotide Polymorphisms - 11/30/2011
CircuLite® Raises $30 Million Series D Financing - 11/22/2011
Asahi Kasei Pharma Corp. Acquires Artisan Pharma to Establish U.S. Presence; Wholly-owned Subsidiary Changes Name to Asahi Kasei Pharma America Corp - 11/07/2011
SCYNEXIS Presents Data Demonstrating that SCY-635 Restores the Body’s Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon - 11/01/2011
Nuron Biotech Initiates Phase 3 Study of Proprietary Recombinant Human Interferon beta-1b in Relapsing Remitting Multiple Sclerosis - 10/21/2011
Rib-X Pharmaceuticals’ RX-04 Program Yields Compounds with In Vitro Potency Against Multi-drug Resistant P. aeruginosa - 10/21/2011
T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida - 10/20/2011
Proteostasis Therapeutics Announces Appointment of Mark J. Enyedy as Chief Executive Officer - 10/19/2011
Arsanis Receives Grant from the Austrian Research Promotion Agency for Pre-Clinical and Clinical Development of Monoclonal Antibodies Against Severe Nosocomial Infections - 10/14/2011
Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics - 10/13/2011
Enanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic - 09/21/2011
Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A - 09/06/2011
Epizyme, Inc. Named a “Fierce 15” Biotech Company for 2011 - 09/06/2011
FORMA Therapeutics Named by FierceBiotech in the 2011 Fierce 15 - 09/06/2011
Rib-X Pharmaceuticals Named a 2011 Fierce 15 Company by FierceBiotech - 09/06/2011
Theraclone Sciences Named a 2011 Fierce 15 Biotech by FierceBiotech - 08/30/2011
Lantos Technologies Appoints Jeffrey C. Leathe as Chairman and CEO and Closes $4.1 Million Financing - 08/17/2011
AIDS Researchers Isolate New Potent and Broadly Effective Antibodies Against HIV - 07/27/2011
Rheonix Announces New SeptiCARD Data Demonstrating Rapid Septicemia Diagnosis - 07/11/2011
Epizyme and Collaborators Publish Paper in Cancer Cell Supporting Use of DOT1L Histone Methyltransferase Inhibitors as Personalized Therapeutics for Genetically-Defined MLL-rearranged Leukemia Patients - 07/11/2011
Patch may replace IV drug infusions – Boston Globe (SpringLeaf Therapeutics) - 07/08/2011
SpringLeaf Therapeutics Announces Second Close of Series B Financing - 07/06/2011
Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics - 06/29/2011
Acetylon Pharmaceuticals Announces Completion of $27 Million Series B Round of Private Investor Financing - 06/27/2011
FORMA Grants Genentech Exclusive Rights to Acquire a Pre-clinical Cancer Program - 06/23/2011
The Leukemia & Lymphoma Society and Epizyme Partner to Develop Personalized Therapeutic for Genetically-Defined Mixed Lineage Leukemia (MLL) Patients - 06/21/2011
Seaside Therapeutics Initiates Phase 2b Study of STX209 in Autism Spectrum Disorders - 06/15/2011
Allegro Diagnostics Names Michael D. Webb President and Chief Executive Officer - 06/02/2011
Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome - 05/31/2011
Excelimmune Completes $10.5 Million Series B Financing - 05/25/2011
Proteostasis Therapeutics & Elan Form Drug Discovery Initiative - 05/18/2011
Seaside Therapeutics Publishes Review of Advances in the Treatment of FXS in ACS Chemical Neuroscience - 05/12/2011
SpringLeaf Therapeutics Raises $15M Series B Financing - 05/11/2011
The Leukemia & Lymphoma Society and Acetylon Pharmaceuticals Partner to Advance the Clinical Development of Acetylon's ACY-1215 Drug Candidate for Multiple Myeloma - 04/25/2011
Acetylon Pharmaceuticals Adds HDAC Biology, Inflammation and Neurodegeneration Experts to its Scientific Advisory Board - 04/18/2011
Idera Pharmaceuticals Publishes Data Demonstrating Novel Gene-silencing Oligonucleotide (GSO) Technology - 04/04/2011
Abbott and Enanta Pressent Positive 12-week Results and 3-day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C - 04/04/2011
Harvard Clinical Research Institute and Saint Luke's Mid America Heart and Vascular Institute Complete Cost-effectiveness Analysis for SAPIEN Transcatheter Heart Valve - 03/10/2011
Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme - 03/03/2011
DUSA Pharmaceuticals Reports Full Year 2010 Corporate Highlights and Financial Results - 02/28/2011
Arsanis Announces Series A Fundraising - 01/19/2011
Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme - 01/19/2011
Theraclone and Pfizer Enter into Infectious Disease and Cancer Antibody Discovery Collaboration - 01/11/2011
Rib-X Pharmaceuticals Raises $20 Million to Advance its Industry-Leading Antibiotics Pipeline - 01/10/2011
Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics - 01/07/2011
Emerald BioStructures Achieves Second Milestone and Expands Collaboration with UCB - 12/15/2010
Adimab Announces New Discovery Programs with Eli Lilly, Genentech and Human Genome Sciences - 12/08/2010
Anchor Therapeutics Publishes Discovery of Novel Pepducin as Potent Agonist of Stem Cell Receptor - 11/18/2010
Decoding Autism - Forbes Magazine (Seaside Therapeutics) - 11/17/2010
Eisai and FORMA Therapeutics Enter into Broad Drug Discovery Collaboration - 11/16/2010
Proteostasis Therapeutics Enters into Research Collaboration with Harvard - 09/28/2010
Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics - 09/10/2010
Good Start Genetics, Inc. Raises $18 Million to Develop and Launch Sequencing‐Based Pre‐Pregnancy Genetic Screening Tes - 09/09/2010
Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders - 09/09/2010
Anchor Therapeutics Enters Into Collaborative Research, Option and License Agreement for its Pepducin Technology - 09/09/2010
CombinatoRx Changes Company Name to Zalicus Inc. - 08/24/2010
Roche and Aileron Enter Multi-target Alliance to Develop Stapled Peptide Drugs for Diseases across Multiple Therapeutic Areas - 08/20/2010
Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates